Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion ...

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Minecraft's latest major update is now available for download that adds new features, a slate of bug fixes via version 3.17 ...

Minecraft's latest update adds a ton of fixes and new features via Bedrock 1.21.100, which appears on consoles as version ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

The market for chronic obstructive pulmonary disease treatment devices is projected to witness substantial growth, fueled by ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

The Gates Foundation committed $2.5 billion through 2030 to support dozens of different approaches for improving women’s ...

Vertex Pharmaceuticals stock was the worst performer in the S&P 500 index in premarket trading after the drugmaker said late Monday it wouldn’t advance its next-generation pain medicine to late stage ...